Skip to main
PBH

PBH Stock Forecast & Price Target

PBH Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 20%
Hold 40%
Sell 0%
Strong Sell 0%

Bulls say

Prestige Consumer Healthcare's stock outlook appears positive due to an increased EBITDA estimate for 2026 and 2027 by approximately $15 million, reflecting higher anticipated sales growth. The company's diverse portfolio, which includes well-established brands like Clear Eyes and Dramamine, is supported by strong organic volume growth expected to accelerate in the latter half of 2025, driven by significant product launches and improved production capacities. Additionally, the company is witnessing positive same-store sales (SSS) trends in both the U.S. and Canada, indicating strengthening consumer demand and potential for further revenue growth.

Bears say

The negative outlook on Prestige Consumer's stock is underpinned by expectations of lower-than-expected revenue growth and potential EBITDA margin compression due to persistent increases in input costs. The company faces significant risks from a weaker operating environment in its primary markets, compounded by challenges such as high material costs and limited acquisition opportunities. Additionally, the need for effective deleveraging is pressing, with high levels of debt potentially hindering financial flexibility in the near future.

PBH has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 20% recommend Buy, 40% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Prestige Brands Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Prestige Brands Holdings (PBH) Forecast

Analysts have given PBH a Buy based on their latest research and market trends.

According to 5 analysts, PBH has a Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $85.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $85.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Prestige Brands Holdings (PBH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.